Corxel Pharmaceuticals raised $287 million in a Series D round to advance CX‑11, an oral small‑molecule GLP‑1 receptor agonist for obesity and overweight patients. The company said funds will accelerate the ongoing U.S. phase II program, launch a global phase II in type 2 diabetes, and begin phase III preparations while supporting additional cardiometabolic programs. The raise signals strong investor appetite for oral incretin candidates.